Apimeds Pharmaceuticals US Inc. shares jumped 132.31% to $5.31 Thursday after its wholly owned subsidiary, MindWave Innovations Inc., announced a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. MindWave will design, develop, deploy and host AQUAEChain using its proprietary Layer-2 infrastructure, a secondary blockchain network designed to support faster or more scalable transactions, and provide technical maintenance and escalation support after launch. AQUAEChain will serve as a registry, marketplace and data-management platform for insured AQUAE Labs Ecosystems Conservation Index Credits, using field-based monitoring, reporting and verification. MindWave will receive service fees and a recurring allocation equal to 20% of all issued and outstanding ALCI Credits on the network, calculated at each quarter-end. The agreement includes an option for a five-year continuing services arrangement after the initial term. The deal expands Apimeds’ digital-asset footprint ahead of MindChain’s planned mainnet launch in October.